- Home
- SWK vs NBIX Comparison
SWK vs NBIX Comparison
Compare SWK & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWK
- NBIX
- Stock Information
- Founded
- SWK 1843
- NBIX 1992
- Country
- SWK United States
- NBIX United States
- Employees
- SWK N/A
- NBIX N/A
- Industry
- SWK Industrial Machinery/Components
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SWK Consumer Discretionary
- NBIX Health Care
- Exchange
- SWK Nasdaq
- NBIX Nasdaq
- Market Cap
- SWK 13.8B
- NBIX 11.8B
- IPO Year
- SWK N/A
- NBIX 1996
- Fundamental
- Price
- SWK $89.25
- NBIX $125.65
- Analyst Decision
- SWK Hold
- NBIX Buy
- Analyst Count
- SWK 7
- NBIX 24
- Target Price
- SWK $98.57
- NBIX $163.91
- AVG Volume (30 Days)
- SWK 2.2M
- NBIX 1.1M
- Earning Date
- SWK 10-29-2024
- NBIX 10-30-2024
- Dividend Yield
- SWK 3.67%
- NBIX N/A
- EPS Growth
- SWK N/A
- NBIX 97.40
- EPS
- SWK N/A
- NBIX 3.73
- Revenue
- SWK $15,381,700,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- SWK N/A
- NBIX $26.97
- Revenue Next Year
- SWK $1.60
- NBIX $16.69
- P/E Ratio
- SWK N/A
- NBIX $33.71
- Revenue Growth
- SWK N/A
- NBIX 25.72
- 52 Week Low
- SWK $77.70
- NBIX $110.52
- 52 Week High
- SWK $110.88
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- SWK 39.72
- NBIX 58.45
- Support Level
- SWK $84.73
- NBIX $115.27
- Resistance Level
- SWK $87.17
- NBIX $129.67
- Average True Range (ATR)
- SWK 2.53
- NBIX 3.37
- MACD
- SWK 0.20
- NBIX 0.10
- Stochastic Oscillator
- SWK 37.60
- NBIX 72.08
About SWK Stanley Black & Decker Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates in two reportable segments namely Tools and Outdoor and Industrial. It generates maximum revenue from the Tools and Outdoor segment. The Tools and Outdoor segment is comprised of the Power Tools Group (PTG), Hand Tools, Accessories and Storage (HTAS), and Outdoor Power Equipment (Outdoor) businesses. Geographically, the company generates revenue from the United States, Canada, Other Americas, Europe, and Asia. It derives a majority of its revenue from the United States.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.